上海建发致新医疗科技集团股份有限公司 关于子公司、参股公司简要情况的说明 深圳证券交易所： 上海建发致新医疗科技集团股份有限公司（以下简称"建发致新"、"公司" 或"发行人"）申请首次公开发行股票并在创业板上市，根据《首次公开发行股 票注册管理办法》 《公开发行证券的公司信息披露内容与格式准则第 58 号——首 次公开发行股票并上市申请文件》等有关规定，现将子公司、参股公司简要情况 说明如下： 截至 2025 年 1 月 31 日，发行人下设控股子公司 97 家，分公司 17 家，无参 股公司。具体情况如下： （一）控股子公司 截至 2025 年 1 月 31 日，发行人下设控股子公司 97 家，具体情况如下： | | | | | | | | | | 主营业务及 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 公司 | | 成立 | | | 注册资本 | 实收资本 | | 注册地和主要 | | 股东构成及 | | | 控 | 其在发行人 | | | 最近一年主要财 | | | | | | | | ...

Company Overview - Seer Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, and was established on February 23, 2004. It was listed on October 31, 2016. The company's main business includes centralized marketing and service for medical testing, as well as the agency, research, production, and sales of in vitro diagnostic products [2]. Business Segmentation - The revenue composition of Seer Medical is as follows: IVD business accounts for 39.91%, SPD business for 38.01%, and pure sales for 22.08% [2]. Financial Performance - For the first half of 2025, Seer Medical reported a revenue of 584 million yuan, a year-on-year decrease of 40.20%. The net profit attributable to shareholders was -56.12 million yuan, representing a year-on-year decrease of 1075.89% [2]. Stock Performance - On September 4, Seer Medical's stock price fell by 2.02%, trading at 29.07 yuan per share, with a total market capitalization of 6.109 billion yuan. The stock has increased by 302.63% year-to-date, but has seen a decline of 12.18% over the last five trading days [1]. Trading Activity - Seer Medical has appeared on the trading leaderboard 37 times this year, with the most recent appearance on August 26, where it recorded a net buy of 146 million yuan. The total buy amounted to 489 million yuan, accounting for 18.85% of total trading volume, while total sales reached 343 million yuan, making up 13.22% of total trading volume [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for Seer Medical was 45,700, a decrease of 1.94% from the previous period. The average circulating shares per person increased by 1.97% to 4,180 shares [2]. Dividend History - Since its A-share listing, Seer Medical has distributed a total of 27.0741 million yuan in dividends, with no dividends paid in the last three years [3]. Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included the Caifeng Advantage Industry Rotation Mixed Fund (011201), which held 643,400 shares, marking it as a new shareholder [3].

Core Viewpoint - The company is focusing on identifying its shortcomings in product development and sales as it expands its digital and streamlined business, considering both internal growth and potential acquisitions to address these gaps [1][2]. Group 1: Product Development - The company has enhanced its research capabilities in information technology and high-consumption areas through self-built teams and investments, reducing the urgency for external demands [1]. - Future needs in new or niche areas may require external acquisitions to strengthen capabilities [1]. Group 2: Sales Strategy - The company recognizes the need to improve its solution marketing capabilities, which differ from simple equipment sales and require tailored solutions based on customer needs and information technology levels [2]. - There are existing gaps in local delivery and sales channels for high-value consumables in overseas markets, prompting the company to consider both internal development and acquisitions, such as the acquisition of DiaSys for its global production and logistics capabilities [2]. Group 3: Business Growth and AI Integration - The company's IVD (in vitro diagnostics) business is projected to be a key growth driver, with expected revenue of 13.765 billion yuan in 2024, marking it as the largest business segment [2]. - The company has successfully penetrated international markets, achieving over 30% year-on-year growth in international IVD revenue [2]. - AI technology is being integrated across the company's three main business lines, enhancing product performance and market competitiveness, with notable innovations such as the clinical application of AI models and comprehensive solutions in medical imaging [3].

Investment Rating - The investment rating for Mindray Medical (300760) is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on growth in international markets and product advancements [1][2]. Core Insights - The report highlights that Mindray Medical achieved a revenue of 36.726 billion yuan in 2024, representing a year-over-year growth of 5.14%. The net profit attributable to the parent company was 11.668 billion yuan, with a slight increase of 0.74% [1]. - The domestic market faced challenges due to weak hospital procurement demand, while international markets benefited from localization efforts and high-end breakthroughs, leading to a 21.28% increase in international revenue [2]. - The IVD (In Vitro Diagnostics) segment remains a key growth driver, with a revenue increase of 10.82% in 2024, and significant international growth exceeding 30% [2][3]. Summary by Sections Financial Performance - In 2024, Mindray Medical's total revenue was 36.726 billion yuan, with a net profit of 11.668 billion yuan. The first quarter of 2025 saw a revenue of 8.237 billion yuan, down 12.12% year-over-year, and a net profit of 2.629 billion yuan, down 16.81% [1][2]. - The projected revenues for 2025-2027 are 40.422 billion yuan, 45.799 billion yuan, and 52.473 billion yuan, with corresponding growth rates of 10.1%, 13.3%, and 14.6% [5]. Business Segments - The IVD business generated 13.765 billion yuan in 2024, marking a 10.82% increase and solidifying its position as the largest business segment. International IVD revenue grew over 30% [2][3]. - The medical imaging segment achieved a revenue of 7.498 billion yuan in 2024, with international growth exceeding 15% [2]. - The life information and support segment faced a decline of 11.11% in revenue, but international markets showed double-digit growth due to high-end customer breakthroughs [2]. Market Dynamics - The report indicates that the domestic market is under pressure, but the international market is thriving due to localization and high-end product breakthroughs, with Asia-Pacific and European regions showing growth rates of 40% and 30%, respectively [2]. - The integration of AI technology across all business lines is expected to enhance competitiveness and market share, with significant advancements in IVD, medical imaging, and life information segments [2][3].